{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+meropenem&page=2",
    "query": {
      "intervention": "IV meropenem",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+meropenem&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T00:34:52.903Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01570192",
      "title": "Clinical Trials to Reduce the Risk of Antimicrobial Resistance",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bacterial Pneumonia"
      ],
      "interventions": [
        {
          "name": "IV meropenem",
          "type": "DRUG"
        },
        {
          "name": "I.V. Meropenem",
          "type": "DRUG"
        },
        {
          "name": "Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h",
          "type": "DRUG"
        },
        {
          "name": "Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.",
          "type": "DRUG"
        },
        {
          "name": "tobramycin nebulization",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2010-09",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-09-29",
      "last_synced_at": "2026-09-25T00:34:52.903Z",
      "location_count": 8,
      "location_summary": "San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "San Mateo",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "North Liberty",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01570192"
    },
    {
      "nct_id": "NCT03329092",
      "title": "A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Complicated Intra-abdominal Infection",
        "Hosptial Acquired Pneumonia",
        "Ventilator Associated Pneumonia"
      ],
      "interventions": [
        {
          "name": "ATM-AVI",
          "type": "DRUG"
        },
        {
          "name": "MTZ",
          "type": "DRUG"
        },
        {
          "name": "MER",
          "type": "DRUG"
        },
        {
          "name": "COL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 422,
      "start_date": "2018-04-05",
      "completion_date": "2023-02-23",
      "has_results": true,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-09-25T00:34:52.903Z",
      "location_count": 5,
      "location_summary": "Tucson, Arizona • Torrance, California • Springfield, Illinois",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03329092"
    },
    {
      "nct_id": "NCT00153634",
      "title": "Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Chronic Bronchitis"
      ],
      "interventions": [
        {
          "name": "IV amikacin",
          "type": "DRUG"
        },
        {
          "name": "PO azithromycin",
          "type": "DRUG"
        },
        {
          "name": "IV ceftazidime",
          "type": "DRUG"
        },
        {
          "name": "PO ciprofloxacin",
          "type": "DRUG"
        },
        {
          "name": "IV meropenem",
          "type": "DRUG"
        },
        {
          "name": "IV piperacillin-tazobactam",
          "type": "DRUG"
        },
        {
          "name": "IV ticarcillin-clavulanate",
          "type": "DRUG"
        },
        {
          "name": "IV tobramycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2004-03",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2008-03-13",
      "last_synced_at": "2026-09-25T00:34:52.903Z",
      "location_count": 8,
      "location_summary": "Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00153634"
    },
    {
      "nct_id": "NCT01381562",
      "title": "GSK2251052 in the Treatment of Complicated Intra-abdominal Infections",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infections, Intestinal"
      ],
      "interventions": [
        {
          "name": "Drug: GSK2251052",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2011-10-03",
      "completion_date": "2012-03-05",
      "has_results": true,
      "last_update_posted_date": "2017-11-29",
      "last_synced_at": "2026-09-25T00:34:52.903Z",
      "location_count": 12,
      "location_summary": "Mobile, Alabama • Long Beach, California • Torrance, California + 9 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Council Bluffs",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01381562"
    },
    {
      "nct_id": "NCT03217136",
      "title": "MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Complicated Intra-Abdominal Infection"
      ],
      "interventions": [
        {
          "name": "Ceftolozane/Tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Metronidazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Days",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Days to 17 Years"
      },
      "enrollment_count": 94,
      "start_date": "2018-04-03",
      "completion_date": "2020-03-16",
      "has_results": true,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-09-25T00:34:52.903Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Orange, California • San Diego, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03217136"
    },
    {
      "nct_id": "NCT06080698",
      "title": "Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gram-negative Bacteremia"
      ],
      "interventions": [
        {
          "name": "Intravenous Antibiotics",
          "type": "DRUG"
        },
        {
          "name": "Oral Antibiotics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1030,
      "start_date": "2024-02-22",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-09-25T00:34:52.903Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Denver, Colorado • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06080698"
    },
    {
      "nct_id": "NCT03485950",
      "title": "Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Other Infectious Diseases"
      ],
      "interventions": [
        {
          "name": "Cefepime",
          "type": "DRUG"
        },
        {
          "name": "Ceftolozane",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin-Tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Tazobactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2018-05-16",
      "completion_date": "2022-02-16",
      "has_results": true,
      "last_update_posted_date": "2022-03-15",
      "last_synced_at": "2026-09-25T00:34:52.903Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03485950"
    },
    {
      "nct_id": "NCT04979806",
      "title": "Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection",
        "Acute Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "Cefepime-zidebactam (FEP-ZID)",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wockhardt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 530,
      "start_date": "2022-08-28",
      "completion_date": "2024-11-25",
      "has_results": true,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-09-25T00:34:52.903Z",
      "location_count": 2,
      "location_summary": "Fort Myers, Florida • Tampa, Florida",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04979806"
    },
    {
      "nct_id": "NCT02168946",
      "title": "Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Tract Infection Complicated",
        "Acute Pyelonephritis",
        "Hospital Acquired Bacterial Pneumonia",
        "Ventilator-associated Bacterial Pneumonia",
        "Bacteremia",
        "Abdominal Infection"
      ],
      "interventions": [
        {
          "name": "Vabomere",
          "type": "DRUG"
        },
        {
          "name": "Best Available Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2014-07",
      "completion_date": "2017-07-21",
      "has_results": true,
      "last_update_posted_date": "2019-03-04",
      "last_synced_at": "2026-09-25T00:34:52.903Z",
      "location_count": 20,
      "location_summary": "Hartford, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02168946"
    },
    {
      "nct_id": "NCT03230838",
      "title": "MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection",
        "Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "Ceftolozane/Tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Days",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Days to 17 Years"
      },
      "enrollment_count": 134,
      "start_date": "2018-04-26",
      "completion_date": "2020-12-03",
      "has_results": true,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-09-25T00:34:52.903Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Orange, California • San Diego, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03230838"
    }
  ]
}